Leadership Overview
Alkermes has 4 executives leading key functions including technology, human resources, executive leadership, and legal affairs.
Driven by patient-inspired science, Alkermes is dedicated to developing and commercializing innovative medicines for complex psychiatric and neurological disorders, aiming to address serious unmet medical needs.
Driven by patient-inspired science, Alkermes is dedicated to developing and commercializing innovative medicines for complex psychiatric and neurological disorders, aiming to address serious unmet medical needs.
Leadership Roles at Alkermes
Blair Jackson - Chief Executive Officer, Elect
Blair Jackson, the Chief Executive Officer, Elect at Alkermes, prepares to guide the company's strategic direction and operational execution. Jackson's impending leadership role focuses on advancing Alkermes' mission to develop and commercialize innovative medicines for individuals with complex psychiatric and neurological disorders. This transition involves a deep understanding of the company's neuroscience expertise and patient-inspired science approach, crucial for addressing conditions like addiction, schizophrenia, and opioid dependence. The Chief Executive Officer, Elect will oversee the integration of scientific research, clinical development, and commercial infrastructure to deliver both marketed therapies and investigational candidates. Blair Jackson's mandate includes driving growth, ensuring financial performance, and reinforcing Alkermes' commitment to tackling serious unmet medical needs in central nervous system diseases, thereby improving patient management and outcomes globally.
James Sellers - Chief Technology Officer
James Sellers, the Chief Technology Officer at Alkermes, directs the company's technological strategy and infrastructure. Sellers oversees the development and implementation of advanced technology solutions that support Alkermes' biopharmaceutical operations, from research and development to commercialization. This leadership role ensures that cutting-edge digital tools and data analytics capabilities are leveraged to accelerate the discovery and delivery of innovative medicines for complex psychiatric and neurological disorders. Sellers' focus includes enhancing operational efficiency through technology, safeguarding sensitive data, and exploring emerging technologies that can further the company's mission in neuroscience. The Chief Technology Officer's initiatives are critical for maintaining Alkermes' competitive edge in a rapidly evolving scientific landscape, ensuring robust systems are in place to support the company's global reach and its commitment to improving patient outcomes in central nervous system diseases.
Stephen Schiavo - Senior Vice President and Chief Human Resources Officer
Stephen Schiavo, the Senior Vice President and Chief Human Resources Officer at Alkermes, shapes the company's talent strategy and cultivates its organizational culture. Schiavo leads all human resources functions, including talent acquisition, employee development, compensation and benefits, and employee relations, ensuring that Alkermes attracts, retains, and develops a high-performing workforce. This executive's responsibilities are central to fostering an environment that supports scientific innovation and patient-focused drug development for complex psychiatric and neurological disorders. By aligning HR initiatives with Alkermes' strategic objectives, Stephen Schiavo ensures the organization has the skilled personnel and supportive culture necessary to advance treatments for addiction, schizophrenia, and other central nervous system diseases. The Chief Human Resources Officer's oversight extends to promoting diversity, equity, and inclusion, and driving employee engagement across the global enterprise.
David Gaffin - Senior Vice President, Chief Legal Officer and Chief Compliance Officer, Alkermes, Inc.
David Gaffin, the Senior Vice President, Chief Legal Officer and Chief Compliance Officer, Alkermes, Inc., directs the company's comprehensive legal and compliance frameworks. Gaffin oversees all legal affairs, including corporate governance, intellectual property, regulatory matters, and litigation, ensuring adherence to global legal standards and ethical practices. This critical role supports Alkermes' biopharmaceutical enterprise in developing and commercializing innovative medicines for complex psychiatric and neurological disorders. The Chief Legal Officer and Chief Compliance Officer ensures that all operations, from research and development to commercial activities, align with stringent compliance requirements and the company's patient-inspired science philosophy. David Gaffin's leadership is essential for mitigating legal risks, protecting the company's assets, and upholding the integrity of Alkermes' pursuit of treatments for conditions such as addiction and schizophrenia.
Explore Leadership Teams in Manufacturing
Baxter International Inc. provides a portfolio of renal and hospital products. The company operates through two segments, Hospital Products and Renal. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums, such as technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy, and additional dialysis services. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, and by patients at home under physician supervision.
Company Leadership
JA
JF
LP
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Company Leadership
CE
ST
Акрихин is a leading Russian pharmaceutical company that has been producing effective, affordable, and high-quality medications since 1936. The company offers a diverse portfolio of over 200 socially significant pharmaceutical products, including prescription and over-the-counter drugs. With a strong focus on research and development, Акрихин actively invests in creating new medications and adheres to international GMP standards in all stages of production. The company aims to serve a wide range of clients, including healthcare professionals and patients in need of reliable medical treatments.
Company Leadership BT
AT
KP
TriRx Pharmaceuticals is a contract development and manufacturing organization specializing in both non-sterile and sterile products, including animal health injectables and packaging solutions. The company offers a wide range of capabilities such as development and analytics, sterile and non-sterile manufacturing, and packaging services. With facilities located in Huntsville, Alabama, and Segré, France, TriRx aims to support customers' commercialization efforts across global markets. Their target clients include pharmaceutical companies looking for advanced solutions to bring their products to market.
Company Leadership RM
KL
JS
SH
Frequently Asked Questions Regarding Alkermes Top Executives and Leadership Team
